BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 12, 2024

National Storage Mechanism | Additional information

RNS Number : 1955S

BioPharma Credit PLC

12 June 2024

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF 2024 ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.

Resolutions	Votes For	%	Votes Against	%	Total Votes	% of Total Voting Rights Voted	Votes Withheld1
1: To receive and accept the annual report and financial statements	558,898,973	99.99%	52,892	0.01%	558,951,865	45.85%	28,112
2: To approve the Directors' Remuneration Report	558,576,994	99.97%	177,879	0.03%	558,754,873	45.83%	225,104
3: To receive and approve the Directors' Remuneration Policy	558,551,021	99.96%	227,616	0.04%	558,778,637	45.84%	201,340
4: To re-elect Harry Hyman as a Director	494,888,417	99.99%	66,478	0.01%	494,954,895	40.60%	64,025,082
5: To re-elect Colin Bond as a Director	558,759,159	99.99%	76,104	0.01%	558,835,263	45.84%	144,714
6: To re-elect Duncan Budge as a Director	494,888,417	88.56%	63,946,846	11.44%	558,835,263	45.84%	144,714
7: To re-elect Stephanie Léouzon as a Director	558,780,785	99.99%	54,478	0.01%	558,835,263	45.84%	144,714
8: To re-elect Sapna Shah as a Director	558,780,762	99.99%	54,478	0.01%	558,835,240	45.84%	144,737
9: To re-elect Rolf Soderstrom as a Director	558,744,159	99.99%	76,104	0.01%	558,820,263	45.84%	159,714
10: To re-appoint Ernst & Young LLP as Auditor to the Company	558,682,815	99.96%	204,636	0.04%	558,887,451	45.84%	92,526
11: To authorise the Directors to determine the remuneration of the Auditor	558,769,161	99.99%	69,478	0.01%	558,838,639	45.84%	141,338
12: To approve the Company's dividend payment policy	558,978,176	100.00%	1,801	0.00%	558,979,977	45.85%	0
13: To authorise the allotment of shares by the Company	556,785,857	99.62%	2,150,350	0.38%	558,936,207	45.85%	43,770
14: To authorise the disapplication of pre-emption rights	556,858,554	99.63%	2,077,653	0.37%	558,936,207	45.85%	43,770
15: To authorise the Company to make market purchases of ordinary shares	558,895,163	99.98%	84,814	0.02%	558,979,977	45.85%	0
16: To authorise the Company to hold general meetings on 14 clear days' notice	558,867,851	99.98%	99,598	0.02%	558,967,449	45.85%	12,528

1.     A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

Copies of resolutions 13 to 16 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

12 June 2024

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

T. +44 (0) 333 300 1950  

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSFIFLEELSESM